<DOC>
	<DOCNO>NCT01921751</DOCNO>
	<brief_summary>This randomized phase II trial study well high standard intensity radiochemotherapy gemcitabine hydrochloride paclitaxel albumin-stabilized nanoparticle formulation ( nab-paclitaxel ) work compare gemcitabine hydrochloride nab-paclitaxel alone treat patient pancreatic cancer remove surgery . Drugs use chemotherapy , gemcitabine hydrochloride nab-paclitaxel , work different way stop growth tumor cell , either kill cell , stop divide stop spread . Radiation therapy use high-energy x-ray kill tumor cell . Drugs , capecitabine , may make tumor cell sensitive radiation therapy . Giving radiation therapy different way add chemotherapy may kill tumor cell . It yet know whether high intensity radiochemotherapy gemcitabine hydrochloride nab-paclitaxel effective standard intensity radiochemotherapy gemcitabine hydrochloride nab-paclitaxel gemcitabine hydrochloride nab-paclitaxel alone treat pancreatic cancer .</brief_summary>
	<brief_title>High Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride Nab-paclitaxel Treating Patients With Pancreatic Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine intensified radiochemotherapy follow gemcitabine ( gemcitabine hydrochloride ) nab-paclitaxel patient unresectable pancreatic cancer show signal improve 2-year overall survival ( OS ) 10 % 22.5 % compare chemotherapy gemcitabine nab-paclitaxel alone . II . To determine standard radiochemotherapy , follow gemcitabine nab-paclitaxel , patient unresectable pancreatic cancer show signal improve 2-year OS 10 % 22.5 % compare chemotherapy gemcitabine nab-paclitaxel alone . SECONDARY OBJECTIVES : I . To evaluate pattern failure ( local systemic progression ) SMAD family member 4 ( SMAD4 ) status intensity radiation therapy . II . To evaluate impact radiochemotherapy OS subset SMAD4 intact patient . III . To evaluate adverse event associate treatment . IV . To evaluate correlation SMAD4 status determine immunohistochemistry ( IHC ) genetic SMAD4 status . OUTLINE : Patients randomize 1 3 treatment arm . ARM I : Patients receive gemcitabine hydrochloride intravenously ( IV ) 30 minute paclitaxel albumin-stabilized nanoparticle formulation IV 30-40 minute day 1 , 8 , 15 . Treatment repeat every 4 week *3 course absence disease progression unacceptable toxicity . Beginning 3-5 week later , patient undergo high-dose intensity-modulated radiation therapy ( IMRT ) 5 day week 6 week ( 28 fraction ) receive concurrent capecitabine orally ( PO ) twice daily ( BID ) 5 day week 6 week . ARM II : Patients receive gemcitabine hydrochloride paclitaxel albumin-stabilized nanoparticle formulation Arm I . Beginning 3-5 week later , patient undergo standard-dose 3-dimensional conformal radiation therapy ( 3D-CRT ) IMRT 5 day week 6 week ( 28 fraction ) receive capecitabine Arm I . ARM III : Patients receive gemcitabine hydrochloride IV 30 minute paclitaxel albumin-stabilized nanoparticle formulation IV 30-40 minute day 1 , 8 , 15 . Courses repeat every 4 week absence disease progression unacceptable toxicity . NOTE : *In Arms I II , 2-6 week completion radiation therapy , patient resume receive gemcitabine hydrochloride paclitaxel albumin-stabilized nanoparticle formulation disease progression unacceptable toxicity . After completion study treatment , patient follow 1 month every 3 month .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically cytologically proven diagnosis adenocarcinoma pancreas prior registration Tumor diameter = &lt; 7 cm Unresectable radiographic criterion ( pancreas protocol compute tomography [ CT ] magnetic resonance image [ MRI ] ) exploration within 30 day prior registration A cell block core biopsy must submit central review analysis SMAD4 status soon possible follow step 1 registration No distant metastasis , base upon follow minimum diagnostic workup : History/physical examination within 30 day prior registration Whole body fludeoxyglucose F 18 ( FDG ) positron emission tomography ( PET ) /CT within 30 day prior registration NOTE : wholebody FDGPET/CT perform , CT chest CT ( MRI ) abdomen pelvis must obtain ( image abdomen pelvis need repeat already include pancreas protocol study ) Zubrod performance status 01 within 30 day prior registration Absolute neutrophil count ( ANC ) &gt; = 1,500 cells/mm^3 Platelets &gt; = 100,000 cells/mm^3 Hemoglobin &gt; = 8.0 g/dl ( NOTE : use transfusion intervention achieve hemoglobin [ Hgb ] &gt; = 8.0 g/dl acceptable ) Cancer antigen 199 ( CA199 ) ; NOTE : event stent place biliary obstruction relieve , CA199 draw post stent placement Creatinine &lt; 2 mg/dl ; glomerular filtration rate ( GFR ) &gt; 50 mL/min ( Cockroft Gault formula ) Bilirubin &lt; 1.5 x upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) = &lt; 2.5 x ULN Activated partial thromboplastin time ( aPTT ) = &lt; 1.2 x ULN Prothrombin time ( PT ) = &lt; 1.2 x ULN Patient must provide study specific informed consent prior study entry Women childbearing potential male participant must practice adequate contraception protocol treatment least 6 month follow treatment For female childbearing potential , negative serum pregnancy test within 30 day prior registration More one primary lesion Prior invasive malignancy ( unless disease free minimum 1095 day [ 3 year ] ) ; nonmelanomatous skin cancer previous early prostate cancer nonrising prostatespecific antigen ( PSA ) eligible Prior systemic anticancer therapy pancreatic cancer ; note prior chemotherapy different cancer allowable Prior radiation therapy abdomen would result overlap radiation therapy field Severe , active comorbidity , define follow : Unstable angina and/or congestive heart failure require hospitalization within last 6 month Transmural myocardial infarction within last 6 month Acute bacterial fungal infection require intravenous antibiotic time registration Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy within 30 day registration Hepatic insufficiency result clinical jaundice and/or coagulation defect ; note , however , laboratory test liver function coagulation parameter require entry protocol Acquired immune deficiency syndrome ( AIDS ) base upon current Centers Disease Control ( CDC ) definition ; note , however , human immunodeficiency virus ( HIV ) test require entry protocol ; protocolspecific requirement may also exclude immunocompromised patient Pregnancy woman childbearing potential , woman discontinue breastfeed men sexually active willing/able use medically acceptable form contraception Prior allergic reaction study drug ( ) involve protocol Preexisting grade 2 great neuropathy Distant metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>SMAD4</keyword>
	<keyword>IMRT</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>FOLFIRINOX</keyword>
	<keyword>high-dose radiotherapy</keyword>
</DOC>